ERCC1表达与食管癌铂类化疗疗效及预后的相关性研究  

Correlation study between expression of ERCC1 and effect and prognosis in the treatment of platinum-based chemotherapy in esophagus cancer

作　　者：丁晓权[1] DING Xiao-quan(Department of Thoracic and Cardiovascular Surgery, the First Hospital of Yulin, Yulin 719000, China)

机构地区：[1]榆林市第一医院胸心外科,陕西榆林719000

出　　处：《临床医学研究与实践》2017年第11期24-25,共2页Clinical Research and Practice

摘　　要：目的探讨ERCC1表达(切除修复交叉互补组1)与食管癌铂类化疗疗效及预后的相关性。方法选择2014年2月至2016年2月我院收治的食管癌患者160例,根据患者ERCC1表达情况分为阴性表达组(85例)和阳性表达组(75例)。给予所有患者含铂类化疗方案进行治疗,并检测ERCC1表达情况。比较两组患者化疗疗效及预后情况。结果阴性组与阳性组化疗疗效相比,无明显差异(P>0.05);阴性表达组患者生存期明显长于阳性表达组(P<0.05)。结论 ERCC1表达与食管癌铂类化疗疗效无明显相关性,但阳性表达提示患者预后较差,生存期短。Objective To discuss the dependency of ERCC 1 expression and platinum based chemotherapy in esophagus cancer. Methods From February 2014 to February 2016, 160 cases of esophagus cancer patients in our hospital were selected, according to the expression of ERCC1, all the patients were divided into the negative expression group （85 cases） and positive expression group （75 cases）. All the patients were given the scheme of containing platinum chemotherapy for treatment, and the expression of ERCC1 was detected. The chemotherapeutic effect and conditions in prognosis of the two groups were compared. Results There was no significant difference in the efficacy of chemotherapy between thetwo groups （P〉0.05）. The lifetime of the negative expression group was significantly longer than that of the positive expression group （P〈0.05）. Conclusion There is no obviously correlation of the ERCC1 expression and platinum based chemotherapy for esophagus cancer, but the positive expression reminds poor prognosis and shorter lifetime.

关 键 词：ERCCL 食管癌 铂类化疗 预后 

分 类 号：R735.2[医药卫生—肿瘤]